A Phase 4 interventional study of Desloratadine and Zyrtec® (cetirizine) in Allergies, sponsored by Organon and Co. Completed. Open to participants aged 6 Years to 11 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-02-09.
Sponsored by Organon and Co · Phase 4, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The primary objective of this study was to determine whether children ages 6-11 years prefer desloratadine RediTabs (2.5 mg) or a marketed competitor (Zyrtec® 5 mg Chewable Tablets). The secondary objectives of this study were to compare acceptance of the two attributes, taste and feeling in the mouth, of desloratadine 2.5 mg RediTabs and Zyrtec® 5 mg Chewable Tablets
1,058 studies on the registry are indexed under Hypersensitivity; 150 are open to participants now.
This study's enrollment of 220 is above the median of 73 across 691 interventional studies indexed under Hypersensitivity.
Browse Hypersensitivity studies →Organon and Co is the lead sponsor of 505 studies on the registry; none are open to participants now.
Of its 23 completed or terminated interventional studies of FDA-regulated products, 18 (78%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects received a single dose of desloratadine RediTab followed 8-10 minutes later by a single dose of Zyrtec chewable tablet followed thereafter by a statement of preference.
Drug: Desloratadine · Drug: Zyrtec® (cetirizine)
Subjects received a single dose of Zyrtec chewable tablet followed 8-10 minutes later by a single dose of desloratadine RediTab followed thereafter by a statement of preference.
Drug: Desloratadine · Drug: Zyrtec® (cetirizine)
desloratadine RediTabs, 1 tablet (2.5 mg),oral administration, single day
Also known as: SCH 034117
Zyrtec® (cetirizine) Chewable Tablets, 1 tablet (5 mg), oral administration, single day
Number of Subjects Who Preferred Desloratadine RediTab or Zyrtec Chewable Tablet.
A product preference questionnaire was completed after the administration of the second study drug. An interviewer instructed the subject "now that you have tasted the two tablets, show us which tablet you like more" and the subject then marked which tablet he/she preferred. If the subject had no preference, the response was recorded accordingly.
Time frame: Following the second dose (8-10 minutes after the first dose)
| Milestone | RediTab/Zyrtec | Zyrtec/RediTab |
|---|---|---|
| Started | 109 | 111 |
| Completed | 109 | 111 |
| Not completed | 0 | 0 |
| Milestone | RediTab/Zyrtec | Zyrtec/RediTab |
|---|---|---|
| Started | 109 | 111 |
| Completed | 109 | 111 |
| Not completed | 0 | 0 |
| Milestone | RediTab/Zyrtec | Zyrtec/RediTab |
|---|---|---|
| Started | 109 | 111 |
| Completed | 109 | 111 |
| Not completed | 0 | 0 |
A product preference questionnaire was completed after the administration of the second study drug. An interviewer instructed the subject "now that you have tasted the two tablets, show us which tablet you like more" and the subject then marked which tablet he/she preferred. If the subject had no preference, the response was recorded accordingly.
| participants | RediTab | Zyrtec | No Preference |
|---|---|---|---|
| Number of Subjects Who Preferred Desloratadine RediTab or Zyrtec Chewable Tablet. | 149 | 33 | 38 |
Collected over 1 day. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| RediTab/Zyrtec | — | 0/109 (0%) | 0/109 (0%) |
| Zyrtec/RediTab | — | 0/111 (0%) | 0/111 (0%) |
| Age, Continuous(years) | Total Population |
|---|---|
| Mean | 8.9 ± 1.65 |
| Sex: Female, Male(Participants) | Total Population |
|---|---|
| Female | 109 |
| Male | 111 |
No study locations are listed for this record.
The record gives a start of Aug 2005, a primary completion of Oct 2005 and a completion of Oct 2005. It does not say whether these dates are actual or estimated.
Results were first posted in Jul 2010, 4 years 9 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Desloratadine · Cetirizine